The abstract explicitly states that T cell-mediated conditions have fewer treatment options and limited understanding compared to other autoimmune neurological diseases. This knowledge gap directly impacts patient care and represents a critical therapeutic need. Gap type: open_question Source paper: Toward curing neurological autoimmune disorders: Biomarkers, immunological mechanisms, and therapeutic targets. (None, None, PMID:39809275)
Landscape Summary: Why do T cell-mediated autoimmune neurological conditions have limited treatment options compared to other subtypes? is a 0.76 priority gap in neuroinflammation. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Why do T cell-mediated autoimmune neurological conditions have limited treatment options compared to other subtypes? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: